Company / Financials
Haemonetics Financials
FY2010-FY2026 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$1.3B
FY2026
Net Income
$117.6M
FY2026
Profit Margin
9.0%
FY2026 · net income / revenue
ROE
-
FY2026 · return on equity
Total Assets
-
FY2026
Total Debt
-
FY2026
Equity
-
FY2026
ROA
-
FY2026 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$1.3BNet Income HistoryProfit after all expenses and taxes$117.6MGross Profit HistoryRevenue minus cost of goods sold$691.5MCost of Revenue HistoryDirect costs of producing goods and services sold$617.5MOperating Income HistoryProfit from core business operations before interest and taxes$164.9MSG&A Expense HistorySelling, general, and administrative expenses$429.8MR&D Expense HistoryResearch and development spending$54.4MInterest Expense HistoryCost of borrowing and debt obligations$19.5MIncome Tax HistoryTotal income tax expense$34.3MEPS (Basic) HistoryBasic earnings per share$2.32+2.2% YoY